Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05877911CT.gov Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy | — | Unknown | — | — | — |
NCT04491942CT.gov Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | — | Active Not Recruiting | — | — | — |
NCT04811703CT.gov Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT04213794CT.gov Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients | — | Terminated | — | — | — |
NCT03373058CT.gov Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery | — | Unknown | — | — | — |
NCT03690739CT.gov Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | — | Terminated | — | — | — |
NCT03842982CT.gov Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) | — | Active Not Recruiting | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03180177CT.gov Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer | — | Unknown | — | — | — |
NCT03025477CT.gov Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer | — | Recruiting | — | — | — |
Show 27 more trialsShow fewer
NCT02489903CT.gov RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | — | Completed | — | — | — |
NCT02435186CT.gov p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | — | Unknown | — | — | — |
NCT02344095CT.gov A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer | — | Completed | — | — | — |
NCT01970722CT.gov Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT02124421CT.gov HOT: HIPEC in Ovarian Cancer as Initial Treatment | — | Active Not Recruiting | — | — | — |
NCT02728492CT.gov Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | — | Completed | — | — | — |
NCT01540565CT.gov Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT02681432CT.gov Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer | — | Unknown | — | — | — |
NCT01472783CT.gov Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation | — | Completed | — | — | — |
NCT01459380CT.gov Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT01366144CT.gov Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | — | Active Not Recruiting | — | — | — |
NCT01275664CT.gov Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer | — | Terminated | — | — | — |
NCT01376752CT.gov Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment | — | Active Not Recruiting | — | — | — |
NCT01264432CT.gov Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT01233505CT.gov Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT01145430CT.gov Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01138137CT.gov N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | — | Withdrawn | — | — | — |
NCT01012817CT.gov Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT00989651CT.gov Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT00892736CT.gov Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | — | Completed | — | — | — |
NCT01669226CT.gov First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer | — | Completed | — | — | — |
NCT00511992CT.gov Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | — | Completed | — | — | — |
NCT00889733CT.gov Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer | — | Terminated | — | — | — |
NCT00335998CT.gov Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies | — | Completed | — | — | — |
NCT00081276CT.gov 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT00083122CT.gov Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT00006942CT.gov Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BB · 67 |
| Mirvetuximab Soravtansine | AstraZeneca | P3 | BBB |
| Trabectedin | AGO Research GmbH | P4 | BBB |
| Irinotecan | OHSU Knight Cancer Institute | P2 | BB |
| Carboplatin | University of Washington | P3 | BB |
| Olaparib | Imunon | P4 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Lenvatinib | University Medical Center Groningen | P4 | BB |
| Durvalumab | AGO Research GmbH | P2 | BB |
+42 more in the Ovarian Carcinoma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Ovarian Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-ovarian-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →